[Monoclonal antibodies ICO-11 in the prognostic evaluation of acute nonlymphoblastic leukemia].
The antigen detectable with monoclonal antibodies ICO-11 was studied in cells of 33 patients with acute lymphoblastic leukemia (ALL) and 47 patients with acute non-lymphoblastic leukemia (ANLL). The incidence rate of antigen-positive cases in ALL comprised 39.4%, in ANLL 35.4%. The presence of antigen in blasts in ALL did not influence the disease prognosis. The presence of ICO-11+ blasts in ANLL was characteristic of the group of patients with more favourable prognosis: a higher survival rate, due to a higher frequency of remissions, a longer life-time in the absence of remission. Basing on the clinico-hematological data ICO-11+ group could not be identified as more favourable prognostically.
Tupitsyn
N N
NN
Volkova
M A
MA
Perilov
A A
AA
Artem'ev
A K
AK
D000328:Adult; D000911:Antibodies, Monoclonal / Q000145:classification / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000276:immunology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000276:immunology* / Q000401:mortality; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000276:immunology / Q000401:mortality; D011379:Prognosis; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor
Monoklonal'nye antitela IKO-11 v otsenke prognoza ostrykh nelimfoblastnykh leĭkozov.